D. E. Shaw & Co., Inc. Tango Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 68,269 shares of TNGX stock, worth $239,624. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,269
Previous 114,827
40.55%
Holding current value
$239,624
Previous $354,000
73.73%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TNGX
# of Institutions
123Shares Held
98MCall Options Held
1.1KPut Options Held
0-
Trv Gp Iv, LLC Boston, MA16.9MShares$59.2 Million88.92% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA10.7MShares$37.7 Million3.54% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$37.3 Million1.14% of portfolio
-
Nextech Invest Ag5.53MShares$19.4 Million3.19% of portfolio
-
Nextech Invest, Ltd. Zurich, V85.53MShares$19.4 Million1.76% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $309M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...